The applications and advantages of Drosophila melanogaster in cancer research
Received date: 2013-06-26
Revised date: 2013-10-21
Online published: 2013-12-20
The common fruit fly, Drosophila melanogaster, has been used to study human disease as a model organism for many years. Many basic biological, physiological, and neurological properties are conserved between mammals and fly. Moreover, Drosophila melanogaster has its unique advantage as a model organism. Recent studies showed that the high level of signaling pathway conservation in tumorigenesis between fly and human and its feasible genetic operation make fly an effective model for oncology research. Numerous research findings showed Drosophila melanogaster was an ideal model for studying the molecular mechanisms of tumorigenesis, invasion and metastasis. This review mainly focuses on the advantages of Drosophila melanogaster in cancer research, established models used for the research of specific cancers and prospective research direction of oncology. It is hoped that this paper can provide insight for cancer research and development of anti-cancer drugs.
Key words： Drosophila melanogaster; tumor; human disease; model
Guitao Huo, Jianjun Lu, Zhe Qu, Zhi Lin, Di Zhang, Yanwei Yang, Bo Li . The applications and advantages of Drosophila melanogaster in cancer research[J]. Hereditas(Beijing), 2014 , 36(1) : 30 -40 . DOI: 10.3724/SP.J.1005.2014.00030
[1] Moloney A, Sattelle DB, Lomas DA, Crowther DC. Alz-heimer’s disease: insights from Drosophila melanogaster models. Trends in Biochemical Sciences, 2009, 35(4): 228–235. <\p>
[2] Feany MB, Bender WW. A Drosophila model of Parkinson’s disease. Nature, 2000, 404(6776): 394–398. <\p>
[3] Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A. Suppression of Hun-tington’s disease pathology in Drosophila by human sin-gle-chain Fv antibodies. Proc Natl Acad Sci USA, 2005, 102(32): 11563–11568. <\p>
[4] Thackray AM, Muhammad F, Zhang C, Di Y, Jahn TR, Landgraf M, Crowther DC, Evers JF, Bujdoso R. Ovine PrP transgenic Drosophila show reduced locomotor acti¬vity and decreased survival. Biochem J, 2012, 444(3): 487– 495. <\p>
[5] St Johnston D. The art and design of genetic screens: Drosophila melanogaster. Nat Rev Genet, 2002, 3(3): 176–188. <\p>
[6] Pandey UB, Nichols CD. Human disease models in Dro-sophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol Rev, 2011, 63(2): 411–436. <\p>
[7] Satta R, Dimitrijevic N, Manev H. Drosophila metabolize 1, 4-butanediol into gamma-hydroxybutyric acid in vivo. Eur J Pharmacol, 2003, 473(2?3): 149–152. <\p>
[8] Wolf FW, Heberlein U. Invertebrate models of drug abuse. J Neurobiol, 2003, 54(1): 161–178. <\p>
[9] Andretic R, Kim YC, Jones FS, Han KA, Greenspan RJ. Drosophila D1 dopamine receptor mediates caffeine- induced arousal. Proc Natl Acad Sci USA, 2008, 105(51): 20392–20397. <\p>
[10] Lloyd TE, Taylor JP. Flightless flies: Drosophila models of neuromuscular disease. Ann NY Acad Sci, 2010, 1184: e1–e20. <\p>
[11] Reiter LT, Potocki L, Chien S, Gribskov M, Bier E. A systematic analysis of human disease-associated gene se-quences in Drosophila melanogaster. Genome Res, 2001, 11(6): 1114–1125. <\p>
[12] Wassarman DA, Therrien M, Rubin GM. The Ras signaling pathway in Drosophila. Curr Opin Genet Dev, 1995, 5(1): 44–50. <\p>
[13] Oro AE, Higgins KM, Hu ZL, Bonifas JM, Epstein EH Jr, Scott MP. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science, 1997, 276(5313): 817–821. <\p>
[14] Dahmane N, Lee J, Robins P, Heller P, Ruizi AA. Activation of the transcription factor Gli1 and the sonic hedgehog signalling pathway in skin tumours. Nature, 1997, 389(6653): 876–881. <\p>
[15] Gonzalez C. Drosophila melanogaster: a model and a tool to investigate malignancy and identify new therapeutics. Nat Rev Cancer, 2013, 13(3): 172–183. <\p>
[16] Ranganathan P, Weaver KL, Capobianco AJ. Notch signaling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer, 2011, 11(5): 338–351. <\p>
[17] Espinoza I, Pochampally R, Xing F, Watabe K, Miele L. Notch signaling: targeting cancer stem cells and epitheli-al-to-mesenchymal transition. Onco Targets Ther, 2013, 6: 1249–1259. <\p>
[18] Malinge S, Ben-Abdelali R, Settegrana C, Radford-Weiss I, Debre M, Beldford K, Macintyre EA, Villeval JL, Vainchenker W, Berger R, Bernard OA, Delabesse E, Pe-nard-Lacronique V. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell Precursor acute lymphoblastic leukemia. Blood, 2007, 109(5): 2202–2204. <\p>
[19] Harrison DA, Binari R, Nahreini TS, Gilman M, Perrimon N. Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J, 1995, 14(12): 2857–2865. <\p>
[20] Vainchenker W, Dusa A, Constantinescu SN. JAKs in pa-thology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol, 2008, 19(4): 385–393. <\p>
[21] Polakis
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号
